The Helleday Team presents potent MTH1 inhibitor ‘Karonudib’ and experimentally addresses the non-active MTH1 inhibitors.
The Helleday Team proudly presents our new potent MTH1 inhibitor Karonudib, which is 20 times more effective than the previously described TH588 inhibitor, recently published in Annals of Oncology. Karonudib stands for: Karolinska nudt1 (MTH1 gene name) inhibitor. In a new report published in Annals of Oncology we present that Karonudib has excellent anti-tumour activity […]